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Background: Localized aggressive periodontitis (LAgP) is an inflammatory disease associated with specific
bacteria, particularly Aggregatibacter actinomycetemcomitans, which can result in early tooth loss. The
bacteria grow as a biofilm known as subgingival plaque. Treatment includes mechanical debridement of the
biofilm, often associated with empirical antibiotic treatment.
Objective: The aims of this study were to test in vitro the sensitivity of A. actinomycetemcomitans JP2 during
planktonic and biofilm growth to doxycycline and to the combination of metronidazole and amoxicillin,
which are two antibiotic protocols commonly used in clinical practice.
Design:T w oin vitro biofilm models were used to test the effects of the antibiotics: a static 96-well plate assay
was used to investigate the effect of these antibiotics on biofilm formation whilst a flow chamber model was
used to examine the effect on established biofilms.
Results: Of the antibiotics tested in this model system, doxycycline was most efficacious with a minimal
inhibitory concentration (MIC) against planktonic cells of 0.21 mg/L and minimal biofilm inhibitory
concentration (MBIC) of 2.10 mg/L. The most commonly prescribed antibiotic regimen, amoxicillin 
metronidazole, was much less effective against both planktonic and biofilm cells with an MIC and MBIC
of 12.0 mg/L and 20.2 mg/L, respectively. A single treatment of the clinically achievable concentration of 10
mg/L doxycycline to sparse A. actinomycetemcomitans biofilms in the flow chamber model resulted in
significant decreases in biofilm thickness, biovolume, and cell viability. Dense A. actinomycetemcomitans
biofilms were significantly more resistant to doxycycline treatment. Low concentrations of antibiotics
enhanced biofilm formation.
Conclusion: A. actinomycetemcomitans JP2 homotypic biofilms were more susceptible in vitro to doxycycline
than amoxicillinmetronidazole.
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L
ocalized aggressive periodontitis (LAgP) is a
rapidly progressive form of periodontal disease
affecting the periodontal tissues of young patients
and can result in tooth exfoliation at a young age (1).
Aggregatibacter actinomycetemcomitans is a Gram-nega-
tive capnophilic bacterium that is regarded as a principal
pathogen associated with LAgP (1, 2). This bacterium is
also associated with systemic infections that can result in
endocarditis (3), meningitis, and brain abscesses (4). A.
actinomycetemcomitans has also been detected in athero-
tic plaques and in placentas of women suffering from
preeclampsia, which is a pregnancy complication evoking
high blood pressure and endangering both the mother
and the fetus (5).
Although root planing and surgical intervention
are the foundations of periodontal therapy, adjunctive
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ness of treatment in individuals with difficult to treat
types of periodontal diseases, such as aggressive period-
ontitis (6). Antimicrobial therapy, usually administered
systemically, offers several advantages in the treatment of
periodontal disease. Not only can it act against pathogens
that have invaded soft tissue, but it can also inhibit
microorganisms at other sites that are relatively inacces-
sible, for example, deep, narrow periodontal pockets.
The literature describes a number of empirical protocols
for the systemic antibiotic treatment of LAgP. These
protocols are mostly based on doxycycline (7, 8) or the
combination of amoxicillin and metronidazole (911).
Other protocols involve clindamycin (12), amoxicillin
(10, 13), or metronidazole (14, 15) as sole agents. There
are currently no universally accepted protocols for
the treatment of A. actinomycetemcomitans-associated
periodontitis.
Clinical isolates of A. actinomycetemcomitans are known
for their ability to form extremely tenacious biofilms
in vitro (16). The ability to form biofilms is essential for
oral bacteria to cause disease, and growth as a biofilm
affords many advantages to bacteria. Most importantly
in the oral cavity, failure of the bacterium to attach and
grow as a biofilm will result in rapid clearance. Biofilms
complicate treatment of periodontitis by protecting bacteria
from the immune system, decreasing antibiotic/antimi-
crobial efficacy and allowing the dispersal of planktonic
cells to distant sites that can aid reinfection (17). The host
inflammatory immune response is not very effective in
killing bacteria within biofilms and may result in damage
to surrounding tissues due to the chronic release of
inflammatory mediators in an effort to overcome the
persistent bacterial challenge. The clinical efficacy of
antimicrobial agents in the oral cavity is largely depen-
dent upon their ability to penetrate or disrupt biofilms
accreted to the tooth surface (dental plaque) and kill
bacteria that make up these biofilms. In vitro screening of
oral antimicrobials is often performed on planktonic
bacterial suspensions; however, this is poorly predictive
of clinical efficacy (18). More recently, researchers have
used biofilm cultures in their in vitro testing of oral
antimicrobials because of the increased resistance of
biofilm bacteria to antimicrobial agents (1924).
The aims of this in vitro study were to evaluate the effi-
cacy of doxycycline versus the combination of amoxicillin
with metronidazole against A. actinomycetemcomitans
JP2 in biofilm models compared with planktonic growth.
Material and methods
Bacterial strains and culture conditions
A. actinomycetemcomitans strain JP2 (ATCC 700685) was
acquired from the American Type Culture Collection. The
JP2 strain was originally isolated from subgingival plaque
of an aggressive periodontitis patient. A. actinomycetem-
comitanswasculturedonTSBVplates(Trypticsoy-Serum-
Bacitracin-Vancomycin) as described by Slots et al. (25)
and maintained in an MK3 anaerobic workstation (Don
Whitley Scientific, Adelaide, Australia) with gas com-
position of 5% CO2,5 %H 2, and 90% N2 (BOC Gases,
Wetherill Park, Australia) at 378C.
Susceptibility of planktonic A.
actinomycetemcomitans to antibiotics
Exponentially growing A. actinomycetemcomitans cells in
Brain Heart Infusion (BHI) medium (Becton Dickinson,
North Ryde, NSW, Australia) were diluted with fresh
medium to give a cell density of 410
8 cells/mL. Doxy-
cycline and amoxicillin were dissolved in de-ionized water
whilst metronidazole was dissolved in 5% dimethylsulf-
oxide in de-ionized water and mixed with the dissolved
amoxicillin in a 1:1 ratio. The bacterial suspension (20 mL)
plus 20 mL of each dissolved antibiotic were added to 160
mL of BHI medium in 96-well flat bottom plates, giving
final antibiotic concentrations ranging between 0.011000
mg/L. The plates were incubated at 378C with periodic
shaking and growth was monitored for 24 h by measuring
Absorbance at a wavelength of 620 nm (AU620) using an
iEMS microplate reader (Labsystems OY Research Tech-
nologies Division, Helsinki, Finland). The minimal in-
hibitory concentration (MIC) was calculated by linear
regression of the AU620 versus antibiotic concentration
data. Fiducial limitswere estimated by converting the 95%
prediction intervals for the linear regression at AU6200
(26). All antibiotics were obtained from Sigma-Aldrich
Corporation (St. Louis, MO, USA).
Effects of antibiotics on A. actinomycetemcomitans
biofilm formation
Todeterminetheeffectofantibiotics onbiofilmformation
astatic96-well plate assaywasused that was adaptedfrom
Izano et al. (23) using the same growth medium, inocula-
tion protocol, and antibiotic solutions as described above.
The plates were incubated for 24 h at 378C after which the
adherent biofilms were rinsed twice with 210 mL of de-
ionizedwater to remove loosely attached cells, followed by
5 min incubation with 0.1% crystal violet. The crystal
violet stained biofilm was then dissolved in 99% ethanol
for 20 min, through repeated pipetting before transfer to a
new 96-well plate. Quantification of the biofilms was
carried out by measuring AU620. The minimal bio-
film inhibitory concentrations (MBIC) were calculated
by linear regression of the AU620 versus antibiotic con-
centration data. Fiducial limitswere estimated byconvert-
ing the95% prediction intervals for the linear regression at
AU6200 (21). The AU620 values at different dose levels
werecomparedbyone-wayanalysisofvariance(ANOVA).
When the overall F-test was significant, the Dunnett
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valuesatdifferentconcentrationsweresignificantlygreater
than the mean U620 values for the untreated control. The
biofilms were also analyzed for viable cells by culture
analysis after serial dilution using TSBVagar as described
previously (24).
Flow cell biofilm culture and confocal laser scanning
microscopy analysis
Based on the results of the static biofilm assay the most
effectiveantibioticwasselectedandusedinaflowchamber
model, to determine the effects of the antibiotic on sparse
immatureandmoreestablishedA.actinomycetemcomitans
biofilms.
Sparse biofilm model
The biofilm culture of A. actinomycetemcomitans JP2 in a
three-channel flow cell system (Stovall Life Science,
Greensboro, NC, USA) located in an MK3 workstation
was based on that described by Dashper et al. (24). The
system was inoculated with 1 mL of an exponentially
growing A. actinomycetemcomitans cultureat 410
8 cells/
mLdiluted1:10withfreshBHI.Thesystemwasincubated
for1hpriortoconstantflow(0.2mL/min)of35%strength
BHI which continued for 24 h. To determine the effect
of the antibiotic on these A. actinomycetemcomitans JP2
biofilms, 1 mL of 10 mg/L doxycycline dissolved in sterile
water, or sterile water as a control, was injected into each
channel of the system and incubated for 30 min. The flow
of medium was then resumed for another 10 min to wash
off any unbound cells, and the adherent biofilms were
stainedwith BacLight stain (Molecular Probes, Invitrogen
Corporation, Carlsbad, CA, USA) in situ as described
previously (22).
Dense biofilm model
For the dense biofilm model, the three-channel flow cell
methodology described above was used, except that a
1:50 diluted A. actinomycetemcomitans inoculum and
50% strength BHI medium were introduced. Confocal
laser scanning microscopy (CLSM) of the bacterial
biofilms was carried out on an LSM Meta 510 Confocal
Microscope with an inverted stage (Carl-Zeiss, Oberko-
chen, Germany) as described previously (22). All CLSM
imageswereanalyzedusingCOMSTATsoftware(27),and
the biometric data were statistically analyzed using the
unpaired Student’s t-test.
Results
Susceptibility of A. actinomycetemcomitans to
antibiotics
Doxycycline and the combination of amoxicillin with
metronidazole were evaluated to determine the MIC and
MBIC. Of these two antibiotic treatments, doxycycline
was the most efficacious with an MIC against planktonic
cells of 0.21 mg/L and an MBIC of 2.10 mg/L, while
the combination of metronidazole and amoxicillin was
much less effective against planktonic cells and biofilms
(Table 1). In the static 96-well plate model after 24 h
of incubation, A. actinomycetemcomitans formed bio-
films that comprised 3.79 9 0.2210
6 cells per well as
determined by cultural analysis. Interestingly, at low
concentrations both doxycycline and the combination of
amoxicillin and metronidazole significantly enhanced
biofilmformation.Atlevelsofupto1.0mg/L,doxycycline
significantly enhanced biofilm formation when compared
with the untreated control (Table 2). There were statisti-
cally significant differences in the mean AU620 values
of the biofilms between concentrations (ANOVA F-test,
pB0.001), with the mean AU620 values increasing from
0.3490.08 for the untreated control to 0.7990.19 at 0.05
mg/L (p0.002) and 0.8390.19 at 1.0 mg/L (p0.001).
Amoxicillinmetronidazole treatment resulted in an even
more significant enhancement of A. actinomycetemcomi-
tans biofilm formation (Table 2) at concentrations up
to 10 mg/L (pB0.001). The mean AU620 values of the
biofilms increased from 0.3990.03 for the untreated
control to 0.8190.22 at 1.0 mg/L (p0.01), 0.7690.08
at 5.0 mg/L (p0.02), and 1.6590.19 at 10.0 mg/L
(pB0.001).
Based on the MIC and MBIC results, doxycycline was
selected to determine its effect on A. actinomycetemco-
mitans biofilms in the flow cell model. To more closely
mimic the clinical environment, a doxycycline concentra-
tion of 10 mg/L was chosen, as this concentration has
been shown to be achievable in gingival crevicular fluid
(GCF) (28).
Flow cell biofilm culture and CLSM analysis
Sparse biofilm
When A. actinomycetemcomitans was cultured in the flow
cell system for 24 h with 35% BHI it formed relatively
sparse biofilms with a maximum thickness of 12.7 mm
(Table 3). These biofilms contained a high percentage of
Table 1. The minimal inhibitory concentration (MIC) and
minimal bioﬁlm inhibitory concentration (MBIC) of dox-
ycycline and amoxicillin  metronidazole determined using
96-well plate static assays
Antibiotic MIC
a (mg/L) MBIC (mg/L)
Doxycycline 0.21 (0.190.23) 2.10 (1.602.80)
Amoxicillin
metronidazole (1:1)
12.0 (10.513.5) 20.2 (17.723.2)
aMIC and MBIC were determined by linear regression using a
minimum of three biological replicates. The fiducial limits shown
in parentheses were determined by converting the 95% predic-
tion intervals for the linear regression at AU6200.
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cells represent cells with disrupted membranes ‘dead’
and green cells those with intact cell membranes ‘live’).
A single 30 min treatment of these A. actinomycetemcomi-
tans biofilms with 10 mg/L doxycycline resulted in a
significant 24% reduction in maximum biofilm thickness
anda59%reductioninaveragebiofilmthickness(Table3).
Statistically significant reductions in biovolume (51%)
and viability (24%) following doxycycline administration
were determined (Table 3). Surface area to biovolume
ratio did not change and the roughness coefficient
Ra increased subsequent to doxycycline administration
(pB0.05) (Table 3).
Dense biofilm
When cultured for 24 h in the flow cell system with 50%
BHI A. actinomycetemcomitans produced dense, struc-
tured biofilms with a maximum thickness of 40.8 mm
(Table 3, Fig. 1). Addition of 10 mg/L doxycycline to
these mature A. actinomycetemcomitans biofilms resulted
in a significant 28% reduction in average biofilm thick-
ness (Table 3, Fig. 2). All other biometric parameters
analyzed did not show any significant effect of doxycy-
cline treatment compared with the untreated biofilms
despite a 12% decrease in viability and 26% reduction in
biovolume (Table 3). There were no significant changes in
surface area to biovolume ratio and the roughness coeffi-
cient Ra subsequent to doxycycline administration (Table 3).
Discussion
In this in vitro study two commonly prescribed antibiotic
protocols were tested for their effectiveness against A.
actinomycetemcomitans JP2 in static 96-well planktonic
and biofilm assays. It has been proposed that A. actino-
mycetemcomitans can be grouped into three major phylo-
genetic lineages: serotype b strains, serotype c strains, and
serotype a, d, e, and f strains. The distribution of A.
actinomycetemcomitans serotypes appears to be related to
geographical location and ethnicity (29, 30). Different
serotypes have differing virulence, with some studies
suggesting that the JP2 clone of serotype b strain has
increasedvirulence.Thiscloneischaracterizedbya530-bp
deletion from the promoter region of the leukotoxin gene
operon, which gives rise to considerably enhanced leuko-
toxin activity (31). The JP2 clone is attributed to descen-
dants of North African populations, but is also prevalent
in LAgP patients from other geographical locations
(32, 33). It has been shown that A. actinomycetemcomitans
JP2 is associated with initiation of periodontal tissue
attachment loss (34), and eradication of JP2 provides
better outcomes of periodontal treatment (3537).
Of the antibiotics examined in this study, doxycycline
produced the best results, inhibiting both planktonic and
biofilm growth at relatively low concentrations (Table 1).
Eick et al. (38) reported the doxycycline MIC for plank-
tonic growth of A. actinomycetemcomitans as 2 mg/L
and the MBIC after 48 h of biofilm culture as 20 mg/L.
Table 2. Effect of low antibiotic concentrations on bioﬁlm formation using 96-well plate static assays
Doxycycline concentration (mg/L) 0 0.05 1.0
Biofilm formation (AU620) 0.3490.08 0.7990.19* 0.8390.19**
Amoxicillinmetronidazole concentration (mg/L) 0 1.0 5.0 10
Biofilm formation (AU620) values 0.3990.03 0.8190.22** 0.7690.08** 1.6590.19**
*ANOVA F-test for the difference in reading relative to the 0 concentration, pB0.002.
**ANOVA F-test for the difference in reading relative to the 0 concentration, p50.001.
Table 3. Effect of a single treatment of 10 mg/L doxycycline on established A. actinomycetemcomitans bioﬁlms in a three-
channel ﬂow cell system. Dense bioﬁlms were produced using inocula of 8 x 10
6 cells in 50% BHI and sparse bioﬁlms were
produced using inocula of 4 x 10
7 in 35% BHI. The biometric parameters were obtained using COMSTAT analysis of CLSM
images and are presented as means 9 standard deviations of three biological replicates
Sparse biofilms Dense biofilms
Biofilm parameter Control Doxycycline 10 mg/L Control Doxycycline 10 mg/L
Biovolume (mm
3/mm
2) 0.309 0.07 0.14790.08
a (51%) 25.6493.89 18.9694.56 (26%)
Average thickness of biofilm (mm) 0.3490.09 0.1490.09
a (59%) 31.6793.36 22.8293.78
a (28%)
Maximum thickness of biofilm (mm) 12.6790.23 9.6091.83
a (24%) 40.7796.49 34.6796.11 (15%)
Surface area: biovolume ratio (mm
2/mm
3) 4.0590.61 4.4590.44 3.1591.6 2.7190.56
Roughness coefficient Ra (unitless) 1.8890.04 1.9490.03
a 0.1590.04 0.2090.04
% Viability 81.094.6 61.597.5
a (24%) 89.193.3 78.499.2 (12%)
aSignificantly different (pB0.05) compared with the relevant control using unpaired Student’s t-test.
Orit Oettinger-Barak et al.
4
(page number not for citation purpose)
Citation: Journal of Oral Microbiology 2013, 5: 20320 - http://dx.doi.org/10.3402/jom.v5i0.20320Whilst Pajukanta et al. (39) reported doxycycline MICs in
the range of 0.25 to 2.0 mg/L using an agar plate based
assay against a variety of clinical strains. The Pajukanta
et al. (39) data are consistent with the MBIC of 2.1 mg/L
againststatic24hbiofilmsobtainedinthisstudy,whichisa
clinically achievable concentration. Doxycycline concen-
trations in GCF havebeen shown to reach up to 10 mg/mL
following a 200 mg per oral dose (28), but usually lower
levels of 2.42.5 mg/mL have been reported (40, 41).
However, utilizing controlled release load-delivery devices
containingdoxycycline,levelsinGCFcanexceed1mg/mL
(40). GCF antibiotic concentrations represent the max-
imumachievableconcentrationsintheperiodontalpocket,
which is the target of antibiotic activity. The efficacious
usage of doxycycline in conjunction with periodontal
treatment has been previously described, and it has
recently been reported as a successful treatment regimen
for young Israeli LAgP patients (42). Several studies have
demonstrated a suppression of the pathogenic subgingival
microbiota during and after doxycycline/tetracycline ad-
ministrationassociatedwithclinicalimprovement(4345).
However, many others have shown that the antibiotics
failed to completely eliminate periodontal pathogens from
periodontal pockets (4649). One of the causes for treat-
ment failure may be the emergence of resistant human
pathogens as a result of the widespread use of antibiotics
(50, 51). An increase in resistance of A. actinomycetemco-
mitans to tetracycline has been reported (52). As emer-
gence of resistant strains may have occurred after the
type strain ATCC 700685 was isolated, the results of this
study should be confirmed with recent clinical isolates.
Furthermore, clinical studies also should be conducted to
confirm the efficacy of therapy with these antibiotics.
Unfortunately very few clinical studies have been con-
ducted using doxycycline despite its widespread clinical
use. In the present study, the combination of amoxicillin
and metronidazole was also analyzed as it is a com-
monly used treatment for periodontitis cases involving A.
actinomycetemcomitans (9, 53), and has been shown to be
efficacious in the treatment of A. actinomycetemcomitans-
associated periodontal disease (53, 54). A synergistic in-
teraction in which amoxicillin enhances metronidazole
uptake by A. actinomycetemcomitans has been reported
(55); however, there are concerns that A. actinomycetem-
comitans strains are developing resistance to both me-
tronidazole and amoxicillin (53, 56). The MIC of 12.0 mg/L
obtained in this study for a 1:1 ratio of amoxicillin
metronidazole is consistent with previously reported
MIC values for metronidazole of 2.064 mg/L (39)
and 1040 mg/L (55). The MBIC of a 1:1 ratio of
amoxicillinmetronidazole of over 20 mg/L that we
obtained in this study is unlikely to be achievable
clinically and as such was not further tested.
Fig. 2. CLSM images of a representative section of an A.
actinomycetemcomitans 24 h dense bioﬁlm cultured in a ﬂow
cell then treated with 10 mg/L doxycycline for 30 min. The
bioﬁlm was stained with BacLight stain. Horizontal (xy)
optodigital sections, each 2 mm thick over the entire
thickness of the bioﬁlm (z), were imaged using a 63
objective at 512 by 512 pixels (0.28 mm per pixel), with each
frame at 143.86 mm (x) by 143.86 mm (y). Live cells ﬂuoresce
green; dead cells ﬂuoresce red.
Fig. 1. CLSM images of a representative section of an A.
actinomycetemcomitans 24 h dense bioﬁlm grown in a ﬂow
cell and stained with BacLight stain. Horizontal (xy)
optodigital sections, each 2 mm thick over the entire
thickness of the bioﬁlm (z), were imaged using a 63
objective at 512 by 512 pixels (0.28 mm per pixel), with each
frame at 143.86 mm (x) by 143.86 mm (y). Live cells ﬂuoresce
green; dead cells ﬂuoresce red.
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clinical efficacyagainst established biofilms it is important
to incorporate hydrodynamic forces which are continu-
ously present in the oral cavity (57). These forces can exert
important shear and clearance effects (58). The flow cell
model with CLSM imaging described in this study allows
a short exposure of biofilms to the antimicrobial agent
and has been used previously to study the effect of a
novel antimicrobial agent on Porphyromonas gingivalis. A.
actinomycetemcomitans formed structured biofilms in
these flow cells and the biovolume of the biofilm after 24
hours of incubation was dependent on dilution of the
growth medium (Table 3). The biofilms formed in this
study were monospecific so as best to model the direct
effect of the antibiotics on the target species, A. actinomy-
cetemcomitans. In vivo the presence of other species of
bacteria in the biofilm may have confounding effects on
antibiotic susceptibility, and this needs to be considered
when relating these data to clinical application. Applica-
tion of a single dose of doxycycline to sparse A. actinomy-
cetemcomitans biofilms resembling early stage biofilm
development in the oral cavity was effective causing a
significant  50% reduction in average biofilm thickness
and biovolume as well as a 24% decrease in viability. It is
likely that any decrease in viability will be underestimated
in our analysis as the Live/Dead stain is reliant on
membrane damage to predict loss of viability and as
doxycycline works by inhibiting protein synthesis, mem-
brane integrity may not be compromised in the relatively
short period of these assays. Doxycycline treatment of
denser established biofilms was far less effective leading
onlytoasignificantreductioninaveragebiofilmthickness.
These data are consistent with those of Takahashi et al.
(59) who showed reduced susceptibility of A. actinomyce-
temcomitans to antibiotics with maturation of the biofilm.
As sparse biofilms develop just after mechanical debride-
mentandmatureintodenserbiofilmsifsufficientnutrients
are available, it is important to emphasize that while
antibiotic administration might be beneficial in assisting
in the suppression of A. actinomycetemcomitans in the
periodontal pocket, effective mechanical removal of bio-
filmsaspartoftheperiodontaltreatmentiscrucialpriorto
chemotherapy.
An interesting and novel phenomenon observed for
both antibiotic protocols tested in this study was enhance-
ment of A. actinomycetemcomitans biofilm formation at
the lower antibiotic concentrations. An increase in bio-
mass has previously been described for newly formed
Staphylococcus epidermidis biofilms in the presence of
vancomycin (60). Those authors suggested that this was
due to the thickening of the staphylococcal cell wall
in response to the antibiotic. An alternative explanation
is that exposure to low concentrations of vancomycin
affected the expression of genes involved in biofilm
production. In support of this hypothesis, sub-inhibitory
concentrations of tetracycline upregulated the expression
of the icaADBC operon leading to the synthesis of a
polysaccharide intercellular adhesin and biofilm forma-
tionbyS.epidermidis (61). Therefore,it is possible that the
antibiotics tested in the current study have a similar effect
on expression of A. actinomycetemcomitans genes that are
involved in biofilm formation.
In summary, doxycycline proved to be highly effective
at inhibiting A. actinomycetemcomitans planktonic growth
and monospecies biofilm formation in vitro and had
significant effects against relatively sparse established
biofilms. Low concentrations of antibiotics enhanced A.
actinomycetemcomitans biofilm formation.
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